How to Fight Insurance Denials for Cystic Fibrosis and Pulmonary Fibrosis Treatments

This guide covers two groups of expensive, life-extending therapies that insurers routinely deny: CFTR modulators for cystic fibrosis (Trikafta, Kalydeco, Symdeko, Orkambi) and antifibrotic drugs for pulmonary fibrosis (Ofev, Esbriet). Despite overwhelming evidence, plans frequently cite outdated policies, impose arbitrary step therapy, or reject patients based on narrow readings of FDA labels—even when the Cystic Fibrosis Foundation (CFF) or American Thoracic Society (ATS) explicitly recommends the drug. Denials are common because these drugs cost $300,000+ per year, and many payers have not updated their medical policies to reflect 2023 FDA label expansions (Trikafta now approved down to age 2) or the CFF's unequivocal guidance that Trikafta is first-line for all eligible genotypes. For pulmonary fibrosis, insurers often deny Ofev for systemic sclerosis-associated interstitial lung disease (SSc-ILD) or progressive fibrosing ILD (PF-ILD), ignoring pivotal trials and the 2022 ATS guideline updates. This guide will show you how to cite the right studies, invoke the right specialist society positions, and build a medical-necessity case your insurer's physician reviewer cannot dismiss.

Why Insurers Deny CFTR Modulators and Antifibrotics

1. "Your mutation is not FDA-approved for this drug"

The most common Trikafta denial. The FDA label lists about 170 specific CFTR variants by name; if your exact mutation isn't printed there, the plan's pharmacy director flags it as "off-label" and denies. In reality, the CFF maintains a continuously updated list of responsive mutations based on in vitro theratype assays and real-world registry data. The CFTR2 database (cftr2.org), curated by Johns Hopkins and the CFF, categorizes each variant's clinical consequence and modulator responsiveness. Plans routinely ignore this; they treat the FDA label as exhaustive when it is illustrative.

2. "You must try Symdeko (or Orkambi) first"—step therapy

Insurers layer on mandatory step-edit protocols requiring you to fail an older, less effective CFTR modulator before "earning" Trikafta. This contradicts the CFF's 2023 Modulator Recommendations, which state Trikafta is standard of care and should be prescribed first-line for all patients age 2 and older with at least one copy of F508del or another responsive mutation. Step therapy not only delays benefit—it can cause irreversible lung function loss during the mandated trial period.

3. "Patient is too young"—pediatric age denials

In April 2023 the FDA expanded Trikafta's indication to children as young as 2 years (and down to 4 weeks for certain gating mutations with Kalydeco). Many payer medical policies still cite the older "age 6 and up" or "age 12 and up" cutoffs. Even when the prescribing physician explains the new label, plans deny based on outdated internal documents that haven't been revised.

4. Ofev or Esbriet denied for non-IPF fibrosis—"not medically necessary"

For idiopathic pulmonary fibrosis (IPF), both drugs are well established. But when a pulmonologist prescribes Ofev for SSc-ILD (systemic sclerosis-associated interstitial lung disease) or progressive fibrosing ILD (PF-ILD), insurers balk. They cite an FDA label limited to IPF, ignoring the SENSCIS trial (NEJM 2019) that led to Ofev's March 2020 FDA approval for SSc-ILD and the INBUILD trial (NEJM 2019) that demonstrated benefit in PF-ILD. The 2022 ATS clinical practice guideline updates and the 2023 American College of Rheumatology (ACR) guideline for SSc-ILD both conditionally recommend nintedanib, yet plans still deny.

5. Hypertonic saline or inhaled antibiotics denied as "not proven" or "experimental"

Less expensive than modulators but still frequently rejected. Plans will deny 7% hypertonic saline (citing only FDA approval for 3%) or brand inhaled tobramycin (Tobi, Bethkis) as "not superior to generic." The CFF 2013 Pulmonary Guidelines (Mogayzel et al., AJRCCM) provide clear, evidence-graded recommendations for both, including the landmark Elkins NEJM 2006 trial for hypertonic saline. Insurers either haven't read these guidelines or choose to ignore them.

---

The Citations Insurers Respect

When you appeal, reference these sources by name and year. Do not invent or approximate; use the exact titles below.

Cystic Fibrosis

• CFF Pulmonary Clinical Practice Guidelines (Mogayzel et al., Am J Respir Crit Care Med 2013) — the foundational chronic-medications guideline covering Pulmozyme, hypertonic saline, inhaled antibiotics (aztreonam, tobramycin), and more.
• CFF CFTR Modulator Therapy Recommendations (2018; updated 2023) — explicitly states Trikafta is standard of care for all eligible patients age 2+; older modulators (Symdeko, Orkambi) are reserved for genotypes ineligible for Trikafta.
• CFTR2 database (cftr2.org) — the authoritative, continuously updated repository of clinical consequences and theratype (modulator responsiveness) for every known CFTR variant. Cite this when your mutation is called "unapproved."
• Elkins et al., N Engl J Med 2006 — hypertonic saline 7% trial showing significant improvement in FEV₁ and reduced exacerbations.
• Middleton et al., Lancet Respir Med 2019 (VX-445-102) and Heijerman et al., Lancet 2019 (VX-445-103) — the pivotal Trikafta (elexacaftor/tezacaftor/ivacaftor) trials in patients ≥12 years with F508del.
• FDA label expansion April 2023 — Trikafta approved for patients age 2 through 5 years who have at least one F508del mutation or certain other responsive mutations.
• CFF Patient Registry Annual Data Report (most recent year) — real-world outcomes across 30,000+ patients; median survival now exceeds 50 years with modulator therapy.

Pulmonary Fibrosis

• ATS/ERS/JRS/ALAT Clinical Practice Guideline for Idiopathic Pulmonary Fibrosis (Raghu et al., Am J Respir Crit Care Med 2018; updated 2022) — conditional recommendation for nintedanib (Ofev) and pirfenidone (Esbriet) in patients with IPF.
• SENSCIS trial (Distler et al., N Engl J Med 2019) — nintedanib reduced rate of decline in FVC in systemic sclerosis–associated ILD; led to FDA approval March 2020.
• INBUILD trial (Flaherty et al., N Engl J Med 2019) — nintedanib slowed progression in patients with progressive fibrosing ILD (PF-ILD), regardless of underlying etiology.
• INPULSIS-1 and INPULSIS-2 trials (Richeldi et al., N Engl J Med 2014) — pivotal nintedanib IPF trials.
• ASCEND and CAPACITY trials (King et al., N Engl J Med 2014; Noble et al., Lancet 2011) — pirfenidone in IPF.
• ACR Guideline for Systemic Sclerosis–Associated ILD (Khanna et al., Arthritis Rheumatol 2023) — conditionally recommends nintedanib for SSc-ILD with evidence of progression.
• Fleischner Society white paper on HRCT patterns in IPF (Lynch et al., Radiology 2018) — defines usual interstitial pneumonia (UIP), probable UIP, indeterminate, and alternative diagnosis patterns; essential for challenging "pattern not proven" denials.

---

How to Argue Against Each Denial Reason

1. "Your mutation is not FDA-approved for this drug"

The insurer's logic: The FDA label for Trikafta lists specific mutations (e.g., F508del, G551D, R117H). If your genotype includes a rarer variant not printed in the label's table, the plan calls it "investigational."

Your counter-argument:

1. Invoke CFTR2. The CFTR2 database (cftr2.org) is the international reference standard, maintained by Johns Hopkins and the CFF. It classifies every known CFTR variant by clinical consequence (CF-causing vs. varying clinical consequence) and notes which variants respond to modulators based on in vitro theratype assays. If CFTR2 lists your mutation as responsive to elexacaftor/tezacaftor/ivacaftor, state that explicitly in your appeal.

2. Cite the CFF's Modulator Eligibility tool. The CFF publishes and regularly updates a list of FDA-approved and CFF-recommended responsive mutations. If your variant is on that list, the insurer's "not FDA-approved" line becomes irrelevant—the leading specialist society in North America endorses it.

3. Explain that the FDA label is illustrative, not exhaustive. When the FDA approves a drug "for patients with at least one mutation that results in CFTR protein being present at the cell surface (gating or residual function mutations)," it prints examples. The label's table cannot list all 2,000+ variants; new variants and theratype data emerge continuously. The CFF 2023 Modulator Recommendations make clear that any patient with a responsive mutation (defined by functional class and theratype) should receive Trikafta.

4. Request external review immediately. Many states require that denials based on "not FDA-approved" go to an independent physician reviewer. That reviewer will typically defer to CFTR2 and CFF guidelines, not the insurer's list.

5. Provide sweat chloride + genotype + current FEV₁. Document classic CF (sweat Cl⁻ >60 mmol/L), the specific CFTR variants with zygosity (e.g., F508del/W1282X compound heterozygous), and objective lung function. If your FEV₁ is declining or you've had frequent pulmonary exacerbations, emphasize that delay causes irreversible damage.

Sample language for your letter:

> "The denial states that [mutation name] is not FDA-approved for Trikafta. However, CFTR2.org—the international, CFF-curated database—classifies [mutation] as [CF-causing / responsive to elexacaftor-tezacaftor-ivacaftor]. The CFF's 2023 Modulator Recommendations explicitly state that Trikafta is standard of care for all patients age 2+ with at least one responsive mutation. The FDA label table is illustrative, not exhaustive; functional theratype data, not a printed list, determines eligibility. I request external review by a pulmonologist familiar with CFTR2."

---

2. Step Therapy—"You must try Symdeko or Orkambi first"

The insurer's logic: Trikafta is expensive; Symdeko and Orkambi are older and slightly less costly. The plan's pharmacy benefit manager (PBM) imposes a mandatory step-edit: fail the cheaper drug first, then "graduate" to Trikafta.

Your counter-argument:

1. CFF 2023 Modulator Recommendations unequivocally place Trikafta first-line. The document states that for patients with at least one F508del mutation (or other responsive mutations), elexacaftor/tezacaftor/ivacaftor should be prescribed without prior authorization hoops. Symdeko and Orkambi are reserved for patients whose genotypes are not eligible for Trikafta.

2. Clinical superiority is not marginal—it is transformational. The VX-445-102 and VX-445-103 trials (Middleton Lancet Respir Med 2019; Heijerman Lancet 2019) showed Trikafta improves FEV₁ by an absolute 10–14 percentage points and dramatically reduces exacerbation rates. Symdeko and Orkambi show smaller, less durable gains. Every month spent on an inferior regimen risks infection, hospitalization, and permanent bronchiectasis.

3. Step therapy violates clinical guidelines. Many states have "step-therapy override" statutes that allow a physician to certify that the preferred drug (Trikafta) is medically necessary and that requiring a trial of a different drug would cause harm or be unlikely to succeed. Your CF center pulmonologist should complete the override form, citing CFF 2023.

4. Document baseline disease severity. If your FEV₁ is already <70% predicted, you've had ≥2 exacerbations in the past year requiring IV antibiotics, or you're being evaluated for transplant, argue that time is critical and step therapy is unethical.

5. Cite the CFF Patient Registry. Real-world data show that patients on Trikafta have superior lung function, weight gain, and quality of life compared to older modulators. The registry enrolls >90% of U.S. CF patients, providing robust comparative effectiveness evidence.

Sample language:

> "The plan's step-therapy policy requires a trial of Symdeko before Trikafta. This contradicts the Cystic Fibrosis Foundation's 2023 Modulator Recommendations, which designate Trikafta as first-line standard of care for all patients with at least one F508del mutation. Clinical trials demonstrate Trikafta's superiority is not incremental but transformative (absolute FEV₁ improvement ~14 percentage points vs. ~4 for Symdeko). Given my current FEV₁ of [X]% and [Y] exacerbations in the past 12 months, delaying Trikafta to satisfy an arbitrary step-edit risks irreversible lung damage. I request an immediate step-therapy override per [state law citation, if applicable] and CFF guidelines."

---

3. Pediatric Age Denials—"Patient is too young"

The insurer's logic: The medical policy was written in 2021 and states "Trikafta is approved for ages 6 and older." Your child is 3 years old.

Your counter-argument:

1. FDA expanded the label in April 2023. Trikafta (elexacaftor/tezacaftor/ivacaftor) is now FDA-approved for patients age 2 through 5 years who have at least one F508del mutation or certain other responsive mutations. Print the updated FDA label and highlight the new indication.

2. Cite the pediatric efficacy and safety data. The approval was based on open-label studies in children age 2–5 showing comparable pharmacokinetics, improvements in sweat chloride, and acceptable safety. The CFF 2023 update incorporates this expansion.

3. Explain that early intervention prevents lung damage. CF lung disease begins in infancy. Structural lung damage (bronchiectasis) on chest CT is detectable by age 3–5 even when spirometry appears normal. Starting CFTR modulator therapy early halts or reverses mucus plugging and inflammation, preserving lung function for life. Delaying until age 6 because the insurer's policy hasn't been updated is medically indefensible.

4. Get a letter from your CF center pulmonologist. CFF-accredited centers treat the majority of U.S. CF patients and stay current with FDA approvals. A letter from the center director or your child's pulmonologist, citing the April 2023 label and CFF guidance, carries significant weight.

5. Request expedited review. Pediatric denials are often reversed quickly once the reviewer realizes the label changed. Ask your physician to request an expedited peer-to-peer review.

Sample language:

> "The denial states that my child is 'too young' for Trikafta, citing an age-6 cutoff. In April 2023, the FDA expanded Trikafta's indication to children age 2 and older with at least one F508del mutation. My child is 3 years old with confirmed CF (sweat chloride [X] mmol/L, genotype F508del/F508del). The CFF 2023 Modulator Recommendations endorse Trikafta for all eligible patients age 2+. Early initiation prevents irreversible structural lung damage. I request immediate approval under the current FDA label."

---

4. Ofev or Esbriet Denied for SSc-ILD or PF-ILD—"Not medically necessary" or "Not FDA-approved"

The insurer's logic: "Ofev is only FDA-approved for idiopathic pulmonary fibrosis. Your diagnosis is systemic sclerosis–associated ILD (or progressive fibrosing ILD), so we deny."

Your counter-argument:

1. Ofev is FDA-approved for SSc-ILD as of March 2020. The SENSCIS trial (Distler et al., NEJM 2019) demonstrated that nintedanib significantly reduced the rate of decline in forced vital capacity (FVC) in patients with SSc-ILD. The FDA expanded the indication; many payer policies have not caught up. Print the current FDA label for Ofev (nintedanib) and circle the SSc-ILD indication.

2. For PF-ILD, cite INBUILD. The INBUILD trial (Flaherty et al., NEJM 2019) enrolled patients with chronic fibrosing ILD (with a progressive phenotype) of multiple causes—hypersensitivity pneumonitis, autoimmune ILD, idiopathic NSIP, unclassifiable ILD. Nintedanib slowed FVC decline by ~50% compared to placebo. The FDA label now includes "chronic fibrosing interstitial lung diseases with a progressive phenotype."

3. Invoke the 2022 ATS/ERS/JRS/ALAT guideline update. While the 2018 IPF guideline gave a conditional recommendation for nintedanib and pirfenidone in IPF, the 2022 update and subsequent ATS statements acknowledge the expanding evidence base for PF-ILD. For SSc-ILD specifically, cite the ACR 2023 SSc-ILD Guideline (Khanna et al.), which conditionally recommends nintedanib in patients with progressive disease.

4. Document progression. Insurers are more likely to approve antifibrotics if you demonstrate a progressive phenotype: ≥10% relative decline in FVC over 12 months, worsening HRCT fibrosis, declining DLCO, or increasing oxygen requirements. Provide serial PFTs and HRCT reports.

5. Confirm the HRCT pattern. For IPF, the high-resolution CT should show UIP or probable UIP pattern per Fleischner Society criteria (Lynch et al., Radiology 2018). If the radiologist wrote "UIP pattern," the insurer cannot claim "diagnosis not proven." For SSc-ILD or other causes, document the extent of fibrosis (% lung involved) and any honeycombing or traction bronchiectasis.

6. Multidisciplinary discussion (MDD) diagnosis. IPF should be diagnosed via multidisciplinary discussion among pulmonologists, radiologists, and (if biopsy performed) pathologists. Note that an MDD consensus diagnosis was reached and cite it.

Sample language for SSc-ILD:

> "The denial states Ofev is 'not FDA-approved' for my systemic sclerosis–associated ILD. In fact, the FDA approved nintedanib for SSc-ILD in March 2020 based on the SENSCIS trial (NEJM 2019), which demonstrated significant slowing of FVC decline. The 2023 ACR Guideline for SSc-ILD (Khanna et al., Arthritis Rheumatol) conditionally recommends nintedanib for patients with progressive disease. My HRCT from [date] shows [X]% fibrosis; my FVC declined from [Y]% to [Z]% over 12 months, meeting criteria for progression. I request immediate approval per the current FDA indication and ACR guideline."

Sample language for PF-ILD:

> "I have progressive fibrosing interstitial lung disease (PF-ILD) with an FVC decline of >10% over the past year despite immunosuppression. The INBUILD trial (NEJM 2019) demonstrated that nintedanib slows progression in patients with chronic fibrosing ILD and a progressive phenotype, leading to FDA approval for this indication. The 2022 ATS guideline update acknowledges this evidence. My diagnosis was confirmed by multidisciplinary discussion at [ILD center]. Denial of Ofev contradicts current FDA labeling and evidence-based guidelines."

---

5. Hypertonic Saline or Inhaled Antibiotics Denied

The insurer's logic: "Hypertonic saline 7% is not FDA-approved; only 3% is." Or: "Brand inhaled tobramycin (Tobi) is not superior to generic nebulized tobramycin."

Your counter-argument:

1. CFF 2013 Pulmonary Guidelines (Mogayzel et al.) give hypertonic saline 7% a strong evidence grade. The Elkins trial (NEJM 2006) used 7% hypertonic saline and showed significant improvement in FEV₁ and reduced exacerbation frequency. The guideline recommends chronic use of hypertonic saline (7% preferred based on trial data, though 3% is an alternative if not tolerated). Cite this directly: "Mogayzel et al., Am J Respir Crit Care Med 2013, recommend hypertonic saline for routine maintenance; Elkins NEJM 2006 used 7%."

2. For inhaled antibiotics, cite the same guideline. Chronic inhaled tobramycin (Tobi, Bethkis, or Tobi Podhaler) is recommended for patients with persistent Pseudomonas aeruginosa infection. Aztreonam (Cayston) is an alternative. Both are FDA-approved and guideline-endorsed. If the plan demands you use compounded or generic tobramycin, note that the CFF guideline evidence base is for the FDA-approved formulations (Tobi solution, Tobi Podhaler), which have known, standardized delivery and particle size. Generic compounded tobramycin has variable bioavailability and may not achieve therapeutic lung concentrations.

3. Document Pseudomonas culture history. Insurers are more likely to approve inhaled antibiotics if you provide microbiology: sputum or throat culture positive for P. aeruginosa on ≥2 occasions in the past year.

4. Provide prior-authorization support from your CF center pharmacy. Most CFF-accredited centers have dedicated CF pharmacists who know how to navigate these denials and can supply letters of medical necessity.

Sample language for hypertonic saline 7%:

> "The plan denied hypertonic saline 7%, stating only 3% is 'approved.' The CFF Pulmonary Clinical Practice Guidelines (Mogayzel et al., AJRCCM 2013) recommend chronic hypertonic saline for maintenance of lung health, citing the Elkins NEJM 2006 trial, which used 7% and demonstrated significant FEV₁ improvement and reduced exacerbations. While 3% may be used if 7% is not tolerated, my physician prescribed 7% per the evidence base. I request approval of the concentration supported by Level I evidence."

Sample language for Tobi:

> "The denial suggests I use generic compounded tobramycin instead of Tobi. The CFF 2013 Pulmonary Guidelines recommend chronic inhaled tobramycin for patients with persistent Pseudomonas aeruginosa (which I have had on culture [dates]). The guideline evidence base and FDA approval are for Tobi solution or Tobi Podhaler, which have standardized particle size and proven lung deposition. Generic compounded tobramycin has variable bioavailability and is not FDA-approved for inhalation. I request approval of the FDA-approved formulation per CFF guidelines."

---

What We Do

We draft physician-ready appeal letters grounded in the guidelines and trials listed above. You answer questions about your diagnosis, genotype or HRCT pattern, lung function, and the exact denial reason. Our system—built with input from CF center pulmonologists and ILD specialists—generates a 1.5–2 page letter citing CFF 2023, CFTR2, ATS 2022, SENSCIS, INBUILD, and every other reference your insurer's medical director must respect. Your physician reviews, signs, and submits. We also flag state-specific step-therapy override forms, external-review deadlines, and whether a peer-to-peer call is your fastest path to reversal.

---

Sources

1. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines: Chronic Medications for Maintenance of Lung Health. Am J Respir Crit Care Med. 2013;187(7):680-689.

2. Cystic Fibrosis Foundation. CFTR Modulator Therapy Recommendations (2018; updated 2023). Available at cff.org.

3. CFTR2 (Clinical and Functional Translation of CFTR). Available at cftr2.org. Johns Hopkins University / Cystic Fibrosis Foundation.

4. Elkins MR, Robinson M, Rose BR, et al. A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis. N Engl J Med. 2006;354(3):229-240.

5. Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. Lancet Respir Med. 2019;7(7):615-626. (VX-445-102)

6. Heijerman HGM, McKone EF, Downey DG, et al. Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation: A Double-blind, Randomised, Phase 3 Trial. Lancet. 2019;394(10212):1940-1948. (VX-445-103)

7. U.S. Food and Drug Administration. Trikafta (elexacaftor/tezacaftor/ivacaftor) label update, April 2023. Indication expanded to age 2+ with certain mutations.

8. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198(5):e44-e68. (2022 update online.)

9. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. N Engl J Med. 2019;380(26):2518-2528. (SENSCIS trial)

10. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718-1727. (INBUILD trial)

11. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2071-2082. (INPULSIS)

12. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22):2083-2092. (ASCEND)

13. Khanna D, Distler O, Avouac J, et al. American College of Rheumatology Guideline for the Treatment of Systemic Sclerosis–Associated Interstitial Lung Disease. Arthritis Rheumatol. 2023;75(12):2065-2079.

14. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic Criteria for Idiopathic Pulmonary Fibrosis: A Fleischner Society White Paper. Radiology. 2018;288(2):480-486.

15. Cystic Fibrosis Foundation Patient Registry. Annual Data Report (most recent year). Available at cff.org/registry.

---

This guide is for educational purposes. It does not constitute legal or medical advice. Always work with your physician and, if needed, a patient advocate or attorney experienced in insurance appeals.